Member of the Month: OrthogenRX, Inc

OrthogenRx, Inc. continues to build on its commercial success with the announcement on November 13, 2017 that the FDA approved (P160057) their Class III Medical Device, TriVisc™.  TriVisc™ will compete, along with the Company’s first product, GenVisc® 850, in the $1.1B U.S. market composed of intra-articular injections of hyaluronic acid for the treatment of osteoarthritis knee pain in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics, e.g., acetaminophen.  TriVisc™ directions for use is for three-weekly injections, and will compete in an addressable $450MM market. 

OrthogenRx transformed itself from a start-up to a commercial company in just 2 yrs.  The Company is cash-flow positive in 2016, just 3 years from initial funding, and has a rich pipeline of follow-on products in development.  It is led by a seasoned management team with decades of experience in product development and commercialization.  OrthogenRx’s unique platform and regulatory approval blueprint for its pipeline of products in development and licensing strategies are projected to approach $200MM in revenue by the end of 2020.

Learn more about this PACT member.

©2020 PACT All Rights Reserved